infect
respiratori
tract
extrem
common
may
involv
bacteria
virus
fungi
combin
pathogen
review
focu
viral
infect
respiratori
viral
syndrom
includ
common
cold
pharyng
tracheobronch
croup
bronchiol
pneumonia
virus
implic
includ
influenza
parainfluenza
enterovirus
adenoviru
respiratori
syncyti
viru
rsv
rhinovirus
rv
coronavirus
like
addit
virus
exist
await
identif
human
metapneumoviru
recent
discov
caus
symptom
young
children
rang
upper
respiratori
tract
urt
diseas
sever
bronchiol
pneumonia
subsequ
japanes
seropreval
studi
metapneumoviru
children
expos
age
attent
focus
respiratori
viru
infect
result
current
epidem
sever
acut
respiratori
syndrom
caus
agent
appear
novel
coronaviru
patholog
result
viru
infect
influenc
host
factor
includ
age
previou
infect
immun
respiratori
system
diseas
immunosuppressioncompromis
diseas
sever
depend
direct
harm
effect
viru
tissu
damag
result
host
antivir
immun
respons
immunopatholog
may
unavoid
viru
erad
ideal
immun
respons
result
earli
elimin
viru
minimum
harm
host
viru
infect
major
trigger
exacerb
obstruct
airway
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
new
treatment
urgent
need
reduc
consider
associ
morbid
mortal
immunopatholog
respiratori
viru
infect
interact
immunopatholog
diseas
current
well
understood
data
concern
viral
immunopatholog
avail
studi
natur
infect
vitro
studi
predominantli
concentr
epitheli
cell
ec
cultur
prepar
peripher
blood
mononuclear
cell
pbmc
vivo
experiment
infect
use
anim
model
human
volunt
rv
frequent
viru
type
identifi
exacerb
rv
infect
asthma
copd
major
focu
center
research
articl
concentr
data
avail
rv
infect
normal
healthi
individu
patient
obstruct
airway
diseas
must
emphas
immunopathogenesi
diseas
result
viru
type
may
differ
respons
cell
epithelium
respiratori
tract
follow
viru
infect
major
influenc
subsequ
respons
consid
detail
review
infect
respiratori
virus
common
caus
wheez
episod
infanc
discuss
exacerb
asthmat
children
exposur
virus
reflect
rapid
accumul
antibodi
rv
particular
rsv
first
year
life
seventi
percent
wheez
episod
first
year
associ
viral
respiratori
infect
rsv
rv
influenza
b
frequent
cultur
children
rsv
caus
bronchiol
potenti
seriou
lower
respiratori
tract
lrt
ill
signific
mortal
associ
increas
risk
subsequ
asthma
potenti
caus
andor
protect
role
virus
develop
subsequ
asthma
remain
controversi
recent
review
asthma
diseas
major
import
affect
children
unit
kingdom
health
cost
condit
enorm
term
time
school
gp
consult
hospit
admiss
mortal
viral
infect
major
asthma
trigger
older
children
adult
role
may
underestim
earli
studi
limit
viral
cultur
serolog
lack
sensit
method
detect
rv
coronavirus
introduct
molecular
biolog
polymeras
chain
reaction
pcr
situ
hybrid
situ
pcr
implic
virus
major
exacerb
direct
evid
implic
virus
come
studi
show
increas
detect
asthma
attack
highest
rate
detect
prospect
studi
sampl
soon
symptom
commenc
longitudin
studi
perform
southampton
uk
upper
respiratori
viral
infect
associ
asthma
exacerb
children
one
hundr
eight
children
age
select
questionnair
basi
episod
wheez
cough
diari
card
use
monitor
respiratori
symptom
peak
flow
virus
detect
report
episod
reduc
peak
expiratori
flow
pef
report
episod
wheez
report
episod
upper
respiratori
symptom
cough
wheez
fall
pef
commonli
identifi
viru
type
rv
relat
studi
viral
urt
infect
urti
strongli
associ
time
hospit
admiss
asthma
children
adult
rate
urti
compar
rate
hospit
asthma
admiss
time
period
hospit
serv
area
cohort
schoolchildren
drawn
strong
correl
found
season
pattern
urti
hospit
asthma
admiss
relationship
stronger
pediatr
adult
admiss
urti
asthma
admiss
frequent
period
school
attend
pediatr
total
admiss
school
holiday
exacerb
adult
asthmat
associ
presenc
respiratori
viru
infect
viru
detect
exacerb
asymptomat
contrast
transtrach
aspir
adult
exacerb
yield
spars
bacteri
cultur
correl
clinic
ill
differ
normal
subject
asthmat
child
develop
infect
rv
coronaviru
rsv
cultur
risk
associ
asthma
attack
asthmat
predomin
virus
rv
rsv
parainfluenza
rv
detect
asthma
attack
adenovirus
enterovirus
coronavirus
also
detect
less
frequent
influenza
found
annual
epidem
although
metapneumoviru
associ
urt
symptom
associ
asthma
small
studi
children
asthma
peopl
atop
asthma
greater
overal
risk
rv
infect
healthi
individu
suffer
frequent
lrti
sever
lrt
symptom
cohabit
coupl
recruit
southampton
uk
one
person
everi
coupl
atop
asthma
one
healthi
particip
complet
daili
diari
card
urt
lrt
symptom
measur
pef
twice
daili
everi
week
nasal
aspir
taken
examin
rv
detect
sampl
particip
asthma
sampl
healthi
particip
group
differ
frequenc
urti
sever
durat
symptom
associ
rv
infect
howev
first
rv
infect
associ
frequent
lrti
particip
asthma
healthi
individu
lrt
symptom
associ
rv
infect
significantli
sever
asthmat
healthi
control
increas
interest
clinic
featur
pathogenesi
copd
reflect
worldwid
import
diseas
million
patient
affect
unit
state
alon
predict
becom
third
lead
caus
death
worldwid
nation
global
initi
launch
manag
guidelin
publish
fewer
studi
examin
epidemiolog
viru
infect
copd
mani
exacerb
copd
occur
without
hallmark
bacteri
volum
purul
sputum
exacerb
associ
symptom
common
cold
frequenc
exacerb
requir
hospit
higher
winter
one
explan
could
increas
frequenc
respiratori
virus
time
year
recent
studi
follow
copd
patient
attend
london
chest
hospit
period
effect
respiratori
viral
infect
time
cours
copd
exacerb
examin
monitor
chang
system
inflammatori
marker
stabl
copd
exacerb
patient
copd
record
daili
pef
increas
respiratori
symptom
nasal
sampl
blood
taken
respiratori
viru
detect
cultur
pcr
serolog
plasma
fibrinogen
serum
interleukin
il
determin
stabl
baselin
exacerb
percent
exacerb
associ
cold
occur
day
exacerb
virus
rv
detect
copd
exacerb
patient
earlier
studi
reli
serolog
viru
cultur
quot
lower
viru
detect
rate
viral
exacerb
associ
increas
dyspnea
higher
total
symptom
count
present
longer
median
symptom
recoveri
period
day
tendenc
toward
higher
plasma
fibrinogen
serum
level
respiratori
virus
detect
rsv
stabl
copd
patient
rsv
identifi
patient
stabl
copd
individu
higher
plasma
fibrinogen
serum
higher
increas
frequenc
exacerb
suggest
persist
rsv
infect
contribut
copd
sever
patient
sever
copd
less
abl
clear
rsv
airway
patient
rsv
result
detect
inflammatori
chang
signific
symptom
persist
infect
virus
associ
progress
copd
particular
adenoviru
appear
persist
latent
form
viral
protein
produc
without
replic
complet
viru
latent
infect
may
amplifi
lung
inflamm
result
cigarett
smoke
anoth
exampl
human
immunodefici
viru
hiv
appear
predispos
pulmonari
emphysema
group
individu
comput
tomographi
scan
evid
emphysema
compar
seroneg
control
smoker
greater
pack
year
consid
respect
frequenc
amongst
smoker
hiv
seroposit
associ
increas
percentag
bronchoalveolar
lavag
bal
lymphocyt
copd
character
acceler
declin
lung
function
period
acut
deterior
symptom
frequent
exacerb
copd
may
acceler
declin
lung
function
year
pef
forc
expiratori
volum
symptom
measur
home
daili
patient
copd
patient
frequent
exacerb
significantli
faster
declin
pef
infrequ
exacerb
often
admit
hospit
longer
length
stay
frequent
exacerb
consist
featur
within
patient
differ
year
studi
associ
increas
rate
bacteri
colon
lower
airway
stabl
immunolog
viru
infect
copd
well
understood
less
data
avail
viru
infect
asthma
yet
subject
human
experiment
infect
studi
studi
clearli
need
view
increas
evid
major
role
virus
caus
copd
exacerb
influenza
parinfluenza
rsv
adenoviru
caus
lower
airway
syndrom
pneumonia
bronchiol
capabl
replic
lower
airway
recent
problem
experiment
rv
infect
model
uncertainti
whether
rv
infect
occur
lower
airway
well
urt
although
nasopharyng
contamin
rule
rv
detect
lower
airway
specimen
sputum
tracheal
brush
bal
revers
cultur
rv
cultur
cell
line
bronchial
ec
origin
replic
demonstr
primari
cultur
bronchial
ec
prefer
rv
cultur
use
argument
lower
airway
infect
evid
replic
occur
temperatur
found
lower
airway
fact
thermistor
studi
show
peripher
lung
airway
temperatur
rise
final
situ
hybrid
show
rv
bronchial
biopsi
subject
follow
experiment
infect
previous
demonstr
nasal
wash
cell
nasal
biopsi
evid
strongli
support
direct
lower
respiratori
epitheli
reaction
initi
event
induct
asthma
exacerb
normal
healthi
volunt
difficult
detect
chang
lung
physiolog
follow
experiment
rv
infect
subject
asthma
andor
allerg
rhiniti
exhibit
increas
pathophysiolog
effect
result
rv
infect
compar
nonatop
nonasthmat
control
detail
monitor
possibl
detect
reduct
pef
home
record
atop
asthmat
patient
acut
phase
experiment
infect
enhanc
sensit
histamin
allergen
challeng
inocul
nonasthmat
atop
rhinit
subject
increas
asthma
symptom
coincid
increas
maxim
bronchoconstrict
respons
methacholin
day
infect
increas
sensit
histamin
asthmat
subject
infect
pronounc
sever
cold
symptom
virus
enter
replic
within
airway
ec
entri
depend
interact
surfac
protein
function
receptor
case
major
group
rv
intercellular
adhes
antibodi
solubl
block
infect
limit
express
airway
epithelium
rv
infect
may
explain
patchi
natur
infect
rv
express
receptor
vitro
vivo
follow
experiment
infect
rv
express
nasal
epithelium
within
h
declin
day
rv
similar
effect
ec
lower
airway
rv
shown
primari
bronchial
ec
vitro
bronchial
biopsi
follow
experiment
infect
asthmat
subject
two
form
murin
favor
viral
infect
bind
neutral
viru
outsid
cell
rv
infect
ec
alter
balanc
favor
infect
induc
mrna
suppress
lipoprotein
receptor
receptor
minor
group
rv
antibodi
block
infect
primari
human
tracheal
ec
phtec
infect
associ
cytokin
induct
increas
transcript
factor
specif
nuclear
factor
nf
express
human
nasal
ec
vitro
exposur
number
inflammatori
cytokin
mediat
includ
tumor
necrosi
factor
protein
myelin
basic
protein
mbp
eosinophil
cation
protein
ecp
particular
may
import
induct
antibodi
decreas
viral
replic
express
phtec
respiratori
ec
line
behav
way
primari
exampl
cell
express
lower
level
constitut
show
ecp
mbp
effect
complex
although
uninfect
cell
cytokin
inhibit
cell
presenc
result
reduc
viral
titer
elev
express
asthmat
airway
may
contribut
increas
symptom
sever
rv
infect
type
cytokin
cell
allergen
challeng
result
conjunctiv
nasal
ec
atop
nasal
brush
ec
atop
basal
level
increas
rel
nonatop
elev
relev
allergen
season
nasal
ec
atop
show
vitro
cultur
allergen
highest
basal
found
nasal
polyp
ec
increas
infect
viral
titer
infect
significantli
higher
polyp
ec
nonatop
atop
nonpolyp
ec
modif
ec
express
therefor
possibl
therapeut
benefit
vitro
rv
increas
express
vascular
primari
bronchial
ec
pbec
cultur
cell
via
mechan
involv
one
action
corticosteroid
inhibit
cell
pbec
pretreat
three
corticosteroid
hydrocortison
dexamethason
mometason
furoat
inhibit
increas
surfac
express
mrna
promot
activ
without
alter
viru
infect
replic
dexamethason
suppress
phtec
inhibit
rv
infect
dexamethason
inhibit
infect
phtec
minor
group
disappoint
studi
inhal
corticosteroid
asthmat
experiment
rv
infect
fail
show
reduc
express
bronchial
biopsi
possibl
longer
cours
andor
higher
dose
inhal
steroid
administr
oral
steroid
might
demonstr
signific
effect
drug
affect
ec
includ
reduc
agent
receptor
antagonist
desloratidineloratidin
inhibit
human
primari
bronchial
epitheli
cell
hpbec
cell
erythromycin
inhibit
infect
phtec
major
group
minor
group
effect
includ
reduct
blockag
rv
rna
entri
endosom
small
reduct
express
ec
activ
recruit
varieti
cell
type
lymphocyt
eosinophil
neutrophil
product
chemokin
cytokin
fig
cell
import
compon
antivir
respons
may
also
contribut
airway
inflamm
dysfunct
asthma
copd
vitro
studi
rv
infect
bronchial
ec
line
primari
human
ec
demonstr
product
wide
rang
proinflammatori
cytokin
chemokin
rant
eotaxin
vivo
cytokin
found
nasal
lavag
nl
associ
rv
infect
ifn
thought
play
import
role
innat
resist
virus
act
cell
surround
tissu
produc
antivir
state
character
express
antivir
activ
gene
isg
two
main
type
ifn
type
type
ec
produc
gene
gene
synthesi
involv
atfjun
ifn
regulatori
factor
irf
current
identifi
activ
occur
respons
signal
includ
dsrna
product
replic
ssrna
virus
rv
rsv
influenza
express
earli
action
activ
ifn
intracellular
signal
pathway
requir
induct
requir
transcript
full
rang
ifn
dna
microarray
analysi
shown
follow
bind
receptor
target
cell
ifn
trigger
complex
signal
pathway
mainli
janu
tyrosin
transduc
activ
transcript
result
transcript
hundr
isg
sever
isg
well
studi
includ
serinethreonin
protein
kinas
pkr
reduc
cellular
mrna
translat
transcript
event
two
enzym
involv
mrna
degrad
synthetas
rnase
l
myxoviru
resist
mx
protein
adenosin
deaminas
involv
rna
edit
ifn
also
cellular
express
mhc
class
ii
molecul
therefor
increas
antigen
present
cell
enhanc
cellular
immun
respons
surprisingli
littl
inform
rv
induct
ifn
ec
inform
avail
influenza
antivir
mx
protein
inhibit
influenza
replic
number
level
influenza
evolv
mechan
resist
action
ifn
exampl
block
pkr
influenza
protein
share
proinflammatori
properti
induct
respons
activ
b
lymphocyt
enhanc
adhes
inflammatori
cell
endothelium
facilit
chemotaxi
potent
antivir
cytokin
vitro
increas
suscept
cultur
ec
infect
shown
stimul
immun
respons
may
also
import
asthma
appear
caus
bronchoconstrict
direct
effect
bronchial
smooth
muscl
vivo
elev
nasal
aspir
children
cold
level
correl
presenc
wheez
addit
induct
rv
infect
result
substanti
increas
vivo
vitro
rel
late
effect
occur
h
infect
may
contribut
symptom
resolut
bronchial
biopsi
demonstr
increas
cell
posit
within
epithelium
submucosa
normal
asthmat
subject
follow
experiment
rv
infect
increas
coincid
peripher
lymphopenia
suggest
increas
recruit
cell
airway
cell
recruit
airway
least
partli
influenc
chemokin
includ
whose
product
ec
virus
balanc
chemokin
product
airway
ec
may
influenc
natur
effect
specif
immun
respons
balanc
may
turn
influenc
chronic
inflamm
found
asthma
copd
thought
effect
antivir
immun
respons
character
product
type
cytokin
evid
suggest
type
respons
rv
defici
individu
asthma
recent
studi
experiment
infect
subject
allerg
rhiniti
asthma
balanc
airway
type
cytokin
induc
sputum
induc
viral
infect
relat
symptom
viral
clearanc
invers
correl
demonstr
ratio
mrna
peak
cold
symptom
addit
subject
still
detect
day
inocul
lower
ratio
acut
cold
phase
clear
viru
studi
clone
cell
suggest
cell
show
differenti
express
chemokin
receptor
increas
express
receptor
protein
chemoattract
monokin
induc
human
cell
increas
express
thymu
chemokin
chemokin
lesser
extent
eotaxin
cell
select
migrat
cell
respons
appropri
chemokin
rant
found
cell
bronchial
biopsi
asthmat
show
high
level
express
signific
level
cell
increas
recruit
cell
airway
result
chemokin
product
ec
could
amplifi
allerg
inflamm
asthmat
airway
microenviron
influenc
pattern
chemokin
express
follow
viru
infect
could
alter
balanc
antivir
immun
respons
neutrophil
recruit
earli
respons
product
ec
activ
neutrophil
promin
featur
sever
asthma
asthmat
nonasthmat
demonstr
signific
increas
neutrophil
day
natur
cold
correl
sputum
similar
result
obtain
taken
day
experiment
infect
asthmat
increas
found
nl
children
natur
cold
experiment
infect
asthmat
result
elev
nl
correl
coldasthma
symptom
score
histamin
asthmat
exacerb
elev
neutrophilia
studi
experiment
infect
asthmat
children
also
demonstr
elev
neutrophilia
nl
acut
infect
level
neutrophil
myeloperoxidas
correl
symptom
sever
asthma
exacerb
asthmat
adult
viru
infect
increas
sputum
neutrophil
increas
neutrophil
elastas
sever
clinic
diseas
studi
suggest
promin
role
neutrophil
tissu
damag
asthma
eosinophil
increas
bronchial
epithelium
biopsi
taken
normal
asthmat
volunt
follow
experiment
rv
infect
small
studi
eosinophil
inflamm
persist
week
asthmat
subject
allerg
rhinit
experiment
rv
infect
increas
bal
eosinophil
follow
segment
allergen
challeng
persist
week
increas
level
ecp
found
sputum
subject
eosinophil
accumul
airway
influenc
rant
eotaxin
produc
airway
ec
vitro
infect
rv
express
rant
increas
nasal
secret
children
natur
asthma
rant
primari
nasal
ec
cultur
rsv
rv
import
bone
marrow
eosinophil
product
eosinophil
surviv
level
increas
viral
urti
level
eotaxin
nl
rise
experiment
infect
data
suggest
pathogen
role
eosinophil
asthma
howev
protect
role
also
possibl
allerg
rhinit
subject
infect
rv
allergen
challeng
sever
durat
cold
symptom
invers
relat
nl
eosinophil
count
infect
eosinophil
may
contribut
viral
antigen
present
eosinophil
pretreat
bind
via
present
viral
antigen
cell
induc
prolifer
secret
eosinophil
antivir
action
guinea
pig
neurotoxin
ecp
rnase
activ
reduc
rsv
infect
role
eosinophil
antivir
immun
respons
thu
requir
evalu
may
import
rang
respiratori
diseas
includ
asthma
viru
infect
produc
constitut
enzym
synthas
no
no
induc
no
express
airway
ec
macrophag
may
benefici
harm
action
gaseou
signal
molecul
regul
mani
aspect
airway
biolog
includ
modul
airway
vascular
tone
caus
relax
via
activ
guanylyl
cyclas
increas
level
intracellular
cyclic
guanosin
monophosph
promot
mucociliari
clearanc
effect
ciliari
motil
reduc
mucou
viscos
convers
may
combin
superoxid
gener
macrophag
neutrophil
inflammatori
infiltr
produc
peroxynitrit
reactiv
speci
power
weapon
bacteria
fungi
toxic
host
cell
may
contribut
immunopatholog
asthma
increas
no
express
elev
level
exhal
fall
corticosteroid
therapi
level
exhal
correl
sputum
eosinophilia
methacholin
respons
contrast
stabl
copd
exhal
level
differ
normal
subject
although
may
increas
exacerb
fact
vitro
cigarett
smoke
reduc
no
mrna
express
murin
cell
line
cell
hpbec
no
appear
least
associ
inflamm
express
induc
proinflammatori
cytokin
includ
lipopolysaccharid
transform
growth
product
may
reduc
indirectli
suppressor
cytokin
induct
arginas
compet
substrat
no
suppress
cell
prolifer
cytokin
product
includ
favor
develop
respons
eosinophilia
appear
promot
eosinophil
chemotaxi
inhibit
eosinophil
apoptosi
interact
no
express
type
balanc
airway
may
contribut
defici
antivir
immun
asthma
rel
import
benefici
antimicrobi
activ
versu
potenti
disadvantag
suppress
depend
specif
pathogen
determin
use
therapi
no
knockout
mice
show
increas
suscept
infect
releas
may
import
nk
target
cell
kill
may
also
possess
antivir
activ
vitro
rv
induc
no
express
hpbec
increas
express
no
mrna
cultur
hpbec
infect
inhibit
product
viral
replic
human
respiratori
ec
line
rsv
also
induc
no
increas
nitrit
level
supernat
cell
hpbec
cultur
bal
fluid
balbc
mice
effect
oppos
dexamethason
unaffect
replic
rsv
cell
inhibit
follow
transfect
retrovir
construct
contain
no
no
inhibitor
abolish
inhibit
replic
influenza
b
kidney
cell
sever
impair
donor
influenza
synthet
dsrna
induc
no
human
airway
ec
induct
appear
depend
activ
pkr
overal
evid
vivo
increas
lower
airway
product
may
benefit
asthma
exacerb
work
guinea
pig
model
suggest
one
mechan
increas
airway
respiratori
viru
infect
inhibit
no
enzym
loss
relax
airway
smooth
muscl
studi
human
asthmat
would
also
suggest
protect
role
exacerb
follow
experiment
infect
patient
greatest
increas
exhal
smaller
increas
histamin
airway
respons
interest
studi
viral
urti
fail
demonstr
increas
nasal
experiment
rsv
rv
influenza
infect
normal
subject
experiment
influenza
infect
increas
oral
day
postinfect
effect
nasal
rais
possibl
respiratori
viru
infect
induct
select
lrt
ec
may
also
contribut
specif
immun
respons
follow
viru
infect
act
cell
particularli
secondari
respiratori
viral
infect
ec
express
mhc
class
costimulatori
molecul
express
vitro
respons
airway
ec
viru
infect
consequ
interact
viru
intracellular
signal
pathway
host
cell
knowledg
mechan
involv
rv
current
limit
activ
signal
pathway
may
depend
receptor
bind
may
occur
viral
replic
within
cell
need
replic
viru
demonstr
inhibit
rv
induct
ec
cytokin
uv
inactiv
one
product
replic
common
ssrna
virus
rv
rsv
influenza
dsrna
shown
activ
compon
signal
pathway
includ
pkr
protein
kinas
result
induct
rant
activ
ec
dsrna
may
direct
indirect
ifn
system
discuss
also
suggest
dsrna
may
activ
ec
bind
role
airway
epithelium
host
defens
discuss
refer
studi
interact
ec
virus
particular
rv
respiratori
viru
infect
common
clinic
import
problem
patient
asthma
copd
virus
common
trigger
exacerb
major
caus
morbid
mortal
rv
common
viru
type
detect
knowledg
immunopathogenesi
exacerb
remain
limit
inform
avail
vitro
vivo
studi
especi
experiment
infect
human
volunt
rv
infect
replic
within
ec
lrt
ec
import
compon
respons
rv
infect
interact
viru
intracellular
signal
pathway
host
cell
result
activ
potenti
antivir
mechan
ifn
product
cytokin
chemokin
influenc
subsequ
induc
respons
although
benefici
facilit
clearanc
viru
respiratori
tract
gener
proinflammatori
mediat
recruit
inflammatori
cell
result
degre
immunopatholog
patient
asthma
copd
may
amplifi
airway
inflamm
research
necessari
determin
whether
modif
ec
respons
respiratori
viru
infect
therapeut
benefit
